Bafna Pharmaceuticals Limited (BOM:532989)
India · Delayed Price · Currency is INR 85.47
-2.52 (-2.86%)
At close: Aug 1, 2025
Verve Therapeutics Balance Sheet
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Cash & Equivalents | 34.33 | 13.96 | 78.09 | 1.73 | 18.04 | Upgrade |
Cash & Short-Term Investments | 34.33 | 13.96 | 78.09 | 1.73 | 18.04 | Upgrade |
Cash Growth | 145.90% | -82.12% | 4414.10% | -90.41% | -78.73% | Upgrade |
Accounts Receivable | 401.74 | 453.95 | 411.49 | 147.8 | 95.6 | Upgrade |
Other Receivables | - | - | - | - | 109.7 | Upgrade |
Receivables | 401.97 | 454.77 | 412.03 | 148.76 | 205.3 | Upgrade |
Inventory | 280.86 | 296.42 | 222.2 | 202.81 | 154.43 | Upgrade |
Prepaid Expenses | - | 4.61 | 3.73 | - | 2.34 | Upgrade |
Other Current Assets | 144.64 | 174.94 | 157.07 | 155.5 | 116.57 | Upgrade |
Total Current Assets | 861.79 | 944.7 | 873.12 | 508.8 | 496.68 | Upgrade |
Property, Plant & Equipment | 660.93 | 507.07 | 402.3 | 388.46 | 367.98 | Upgrade |
Long-Term Investments | 0.01 | - | - | - | - | Upgrade |
Other Intangible Assets | - | 17.7 | 15 | - | - | Upgrade |
Other Long-Term Assets | 8.07 | 7.35 | 5.42 | 4.19 | - | Upgrade |
Total Assets | 1,531 | 1,477 | 1,296 | 901.45 | 864.66 | Upgrade |
Accounts Payable | 309.45 | 354.22 | 284.61 | 124.05 | 106.92 | Upgrade |
Accrued Expenses | 13.83 | 28.03 | 27.38 | 33.39 | 21.5 | Upgrade |
Short-Term Debt | - | 100.11 | 119.09 | 45.92 | 100 | Upgrade |
Current Portion of Long-Term Debt | 141.7 | 36.25 | 25.81 | 11.51 | 5 | Upgrade |
Current Income Taxes Payable | - | 2.16 | 0.81 | 0.9 | - | Upgrade |
Current Unearned Revenue | 1.66 | 0.99 | 0.99 | 0.66 | - | Upgrade |
Other Current Liabilities | 51.88 | 19.07 | 6.07 | 3.71 | 9.67 | Upgrade |
Total Current Liabilities | 518.52 | 540.83 | 464.76 | 220.13 | 243.09 | Upgrade |
Long-Term Debt | 140.29 | 107.53 | 84.33 | 53.17 | 52.86 | Upgrade |
Long-Term Unearned Revenue | 19.14 | 16.15 | 12.19 | 8.51 | - | Upgrade |
Other Long-Term Liabilities | 4.78 | 3.92 | - | - | 1 | Upgrade |
Total Liabilities | 682.73 | 668.43 | 561.29 | 281.81 | 296.95 | Upgrade |
Common Stock | 236.56 | 236.56 | 236.56 | 236.56 | 236.56 | Upgrade |
Additional Paid-In Capital | - | 753.77 | 753.77 | 753.77 | 753.77 | Upgrade |
Retained Earnings | - | -451.76 | -525.6 | -640.51 | -692.43 | Upgrade |
Comprehensive Income & Other | 611.5 | 269.81 | 269.81 | 269.81 | 269.81 | Upgrade |
Total Common Equity | 848.07 | 808.39 | 734.55 | 619.64 | 567.71 | Upgrade |
Shareholders' Equity | 848.07 | 808.39 | 734.55 | 619.64 | 567.71 | Upgrade |
Total Liabilities & Equity | 1,531 | 1,477 | 1,296 | 901.45 | 864.66 | Upgrade |
Total Debt | 281.99 | 243.89 | 229.24 | 110.59 | 157.86 | Upgrade |
Net Cash (Debt) | -247.66 | -229.93 | -151.15 | -108.86 | -139.82 | Upgrade |
Net Cash Per Share | -10.49 | -9.72 | -6.39 | -4.60 | -5.90 | Upgrade |
Filing Date Shares Outstanding | 23.84 | 23.66 | 23.66 | 23.66 | 23.66 | Upgrade |
Total Common Shares Outstanding | 23.84 | 23.66 | 23.66 | 23.66 | 23.66 | Upgrade |
Working Capital | 343.27 | 403.87 | 408.35 | 288.67 | 253.59 | Upgrade |
Book Value Per Share | 35.58 | 34.17 | 31.05 | 26.19 | 24.00 | Upgrade |
Tangible Book Value | 848.07 | 790.69 | 719.55 | 619.64 | 567.71 | Upgrade |
Tangible Book Value Per Share | 35.58 | 33.42 | 30.42 | 26.19 | 24.00 | Upgrade |
Land | - | 1.93 | 1.93 | 1.93 | 1.93 | Upgrade |
Buildings | - | 251.51 | 250.78 | 245.71 | 225.35 | Upgrade |
Machinery | - | 741.42 | 693.86 | 631.75 | 568.38 | Upgrade |
Construction In Progress | - | 104.96 | - | - | 8.31 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.